Apogee Therapeutics, Inc.
APGE
Rankning i aktier
#2363
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aktiekurs
$135.07
Senast synkroniserad: 2026-09-04
Marknadsvärde
$8.36B
Förändring (1 dag)
0.00%
Förändring (1 år)
141.76%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
P/B-tal för Apogee Therapeutics, Inc. (APGE)
P/B-tal per October 2026 TTM: 8.53
Enligt Apogee Therapeutics, Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 8.53. I slutet av 2023 hade företaget ett P/B-tal på 3.73.
Historik för P/B-tal för Apogee Therapeutics, Inc. från 2022 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
